HilleVax, Inc. (NASDAQ:HLVX) Receives Average Rating of “Hold” from Brokerages

HilleVax, Inc. (NASDAQ:HLVX) has been assigned a consensus recommendation of “Hold” from the six brokerages that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold recommendation. The average 12 month target price among brokerages that have covered the stock in the last year is $3.00.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $2.00 target price on shares of HilleVax in a research note on Monday.

Institutional Investors Weigh In On HilleVax

Several institutional investors and hedge funds have recently made changes to their positions in HLVX. Intech Investment Management LLC acquired a new stake in HilleVax during the fourth quarter worth about $26,000. SG Americas Securities LLC boosted its position in HilleVax by 61.6% in the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock worth $38,000 after purchasing an additional 6,916 shares in the last quarter. Ieq Capital LLC boosted its position in HilleVax by 71.1% in the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock worth $47,000 after purchasing an additional 9,344 shares in the last quarter. Bank of Montreal Can grew its stake in shares of HilleVax by 47.1% during the 4th quarter. Bank of Montreal Can now owns 35,763 shares of the company’s stock worth $74,000 after purchasing an additional 11,459 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of HilleVax by 328.0% during the 4th quarter. Russell Investments Group Ltd. now owns 38,236 shares of the company’s stock valued at $79,000 after purchasing an additional 29,303 shares in the last quarter. 86.42% of the stock is currently owned by institutional investors and hedge funds.

HilleVax Price Performance

Shares of NASDAQ:HLVX traded down $0.11 during trading hours on Monday, hitting $1.49. The company’s stock had a trading volume of 87,943 shares, compared to its average volume of 174,122. The firm’s fifty day moving average price is $1.82 and its 200 day moving average price is $1.86. HilleVax has a 52 week low of $1.47 and a 52 week high of $16.66. The company has a market capitalization of $73.96 million, a price-to-earnings ratio of -0.48 and a beta of 0.76.

HilleVax (NASDAQ:HLVX) last posted its earnings results on Friday, March 28th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). On average, equities research analysts predict that HilleVax will post -2.64 earnings per share for the current fiscal year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.